Mutated G proteins as drug targets

G proteins, members of the GTPase superfamily, are central mediators of signal transduction downstream of G protein-coupled receptors (GPCRs). Despite their critical roles in normal physiology and the high intrinsic affinity for endogenous ligands, G proteins have traditionally been considered 'undruggable'. Recent advances have led to the development of small molecules and peptides targeting wild-type (WT) G proteins; however, none have yet progressed to clinical application. By contrast, somatic and germline mutations in G proteins have been increasingly implicated in oncogenesis and neurodevelopmental disorders. Thus, targeting mutant G proteins represents a promising therapeutic strategy, offering the potential for selective intervention while sparing normal signaling. In this review, we provide an overview of known G protein modulators and pathogenic mutations recently reported in the literature, and discuss emerging opportunities for therapeutic targeting of mutant G proteins.